Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO

Core Viewpoint - Novo Nordisk A/S is facing a class action securities lawsuit due to alleged securities fraud related to disappointing results from their "REDEFINE 1" trial for CagriSema, which fell short of expectations [1][2] Group 1: Lawsuit Details - The class action lawsuit seeks to recover losses for investors affected by the alleged fraud between November 2, 2022, and December 19, 2024 [1] - The "REDEFINE 1" trial results indicated that patients treated with CagriSema experienced a weight loss of 22.7% after 68 weeks, below the company's target of at least 25% [2] - Following the announcement of the trial results, Novo's stock price dropped by $18.44, closing at $85.00 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until March 25, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant compensation for shareholders and has extensive experience in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]